Your Account
close button

Use our patient tools for secure, convenient, 24/7 access. Learn more

OR

This facility is a member of


Connect with us:

Uterus / Endometrium Cancer

   

Advanced, Persistent or Recurrent Disease

A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus [GOG 0130F]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Evaluation of BIBF 1120 (IND #113086) in the Treatment of Recurrent or Persistent Endometrial Carcinoma [GOG 0229K] 

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Trial of AMG 386 (IND#111071), a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium [GOG 0229L] Temporarily closed to accrual

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus  [GOG 238]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Randomized Phase III Trial of Cisplatin and Tumor-Volume-Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma  [GOG 0258]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

GROningen International Study on Sentinel Nodes in Vulvar Cancer (GROINNSS-V) II: An Observational Study [GOG 0270]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase III Randomized Trial of Pulse Actinomycin-D versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia  [GOG 0275]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrently with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva [GOG 0279]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

Sarcomas

A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus [GOG 0130F]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus [GOG 0131H] 

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus [GOG 0230D}

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Evaluation of MLN 8237 (IND #113149, NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus {GOG 0231D]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) plus GCSF with Bevacizumab (NSC #704865, IND #7921) versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) plus G-CSF with Placebo in the     Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus.  NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #7921) [GOG 0250]

Pricipal Investigator:
S. K. Sharma, MD
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly-Diagnosed Stage I-IV or Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus [GOG 0261]

Pricipal Investigator:
S. K. Sharma, MD
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase III Randomized Trial of Gemcitabine (NSC # 613327 plus Docetaxel (NSC # 628503) followed by Doxorubicin (NSC # 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma [GOG 0277]

Pricipal Investigator:
S. K. Sharma, MD
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

 

Share